Supplementary Table 1. The table displays the in vitro and in vivo references to figure 8, overview of truncated GIP variants. Percentages compared to full agonist GIP(1-42) or GIP(1-30) results. Affinity data is in italic. GIP = species sequence of ligand, RL = GIP(1-42) radioligand, GIPR = GIP receptor, B = bovine, P = porcine, R = rat, M = mouse, Ha = hamster, Hu = human, US = unknown species, UC = unknown concentration.
GIP RL GIPR
Results GIP GIPR Results GIP(1-3) B P Ha Pancreas membranes: No binding (10 µM) (Maletti et al., 1986) GIP(1-6)NH2 US P R CHO-cells: No cAMP production, no binding (10 µM) (Hinke et al., 2001) GIP(1-7)NH2 US P R CHO-cells: No cAMP production, no binding (10 µM) GIP(1-13)NH2 P P R CHO-cells: 13% cAMP (20 µM), 5% binding (10 µM)
GIP(1-14)NH2 P P R CHO-cells: 73% cAMP (20 µM), 28% binding (10 µM) P R 26% insulin release (5 nM), sig. glucose decrease P R Pancreas perfusion: No insulin release (10 ng/ml) (Pederson and Brown, 1976) GIP ( et al., 1996 , Morrow et al., 1996 , Gallwitz et al., 1993 US R Pancreas: Full insulin response (1 nmol/kg/h) Stomach: 10-fold lower gastric acid-inhibition (10 nmol/kg/h) (Rossowski et al., 1992) GIP(1-30)OH Hu P P CHO-cells: 11-fold decreased IC50 than pGIP(1-42) Hu R Pancreas perfusion: Full insulin response (1 nM) (Wheeler et al., 1995) GIP(1-38) P R Pancreas perfusion: Full insulin response (UC) (Moroder, 1978) GIP(1-39) B R Pancreas perfusion: Full insulin response (1 nM) (Sandberg et al., 1986) GIP(6-30)NH2 P P R CHO-cells: cAMP: 58% inhibition (0.1 µM), equal IC50 (Gelling et al., 1997) GIP ( Anesthesia: 100 nmol/kg abolishes 1.5 nmol/kg GIP-insulin secretion and reduces meal-induced insulin with 55%. (Hinke et al., 2001 , Tseng et al., 1996 P P R CHO-cells: 10 µM decreases 1 nM GIP-cAMP by 34% IC50 177 nM US R 3 µg/250 g: 30% inhibition of glucose-induced insulin, 15% plasma glucose, 54% meal-induced insulin. 20 µg/kg reduced glucose-uptake 30%. (Tseng et al., 1999 , Gelling et al., 1997 GIP(10-30) P P R CHO: 50%-inhi. cAMP (10 µM). 187 fold decreased IC50 (Gelling et al., 1997) GIP(15-30)NH2 P P R CHO: cAMP, antagonism (10 µM): 30 % of GIP(7-30) IC50 1400 nM P R Pancreas perfusion: No insulin release (1 ng/ml) (Hinke et al., 2001 , Morrow et al., 1996 GIP(16-30)NH2 P P R CHO: cAMP, antagonism(10 µM): 20 % of GIP (7- (Maletti et al., 1986) GIP(21-30)NH2 P R L293-cells: No activity, no inhibition of pGIP(1-42) (Tseng et al., 1996) GIP(21-26) Hu P P CHO-cells: No binding (1 µM) (Wheeler et al., 1995) GIP(3-42) US R BRIN-BD11: 30% cAMP (EC50 ≈ nM) and 1 µM inhibits 45%. 70% inhibition of insulin release by 1 µM (Kerr et al., 2011) P US R COS-cells: No cAMP IC50 ≈ nM, 10 fold reduced affinity P R Pan.perfusion: Inhibition of insulin, IC50 138 nM (Deacon et al., 2006) GIP(4-42) B P Ha Pancreas membranes: IC50 5 nM (Maletti et al., 1986) US R BRIN-BD11: 50% cAMP, 30% inhibition of insulin (1 µM) M Ob/ob: Glucose increase (25 nmol/kg) (Kerr et al., 2011) US US CHL-cells: 1 µM inhibits cAMP (0.1 µM GIP) 40% BRIN-BD11: 1 µM inhibits insulin (0.1 µM GIP) 23% (Gault et al., 2002) GIP(5-42) US R BRIN-BD11: 35% cAMP (1 µM), insulin-inhibition 70% M Ob/ob: Glucose increase (25 nmol/kg) (Kerr et al., 2011) GIP(6-42) US R BRIN-BD11: 80% cAMP (1 µM), insulin-inhibition 40% GIP(7-42) US R BRIN-BD11: 65% cAMP (1 µM), insulin-inhibition 55% M Ob/ob: Glucose increase (25 nmol/kg) GIP(8-42) US R RINm5F: 30-fold decrease of GIP(1-42) potency (5 µM) (Cheng et al., 2015) US R BRIN-BD11: 16% cAMP (1 µM), insulin-inhibition 65% M Ob/ob: 1.4 fold glucose increase, sig. insulin decrease (25 nmol/kg) (Kerr et al., 2011) GIP(9-42) US R BRIN-BD11: 100% cAMP (1 µM), 100% insulin secretion GIP(13-42) H H Isothemal titration calorimetry: 6-fold lower affinity (Parthier et al., 2007) GIP(15-42) P P R CHO: cAMP, antagonism (10 µM): 40 % of GIP(7-30) IC50 1270 nM P R Pancreas perfusion: 40% insulin response (10ng/ml) (Kerr et al., 2011 , Hinke et al., 2001 , Pederson and Brown, 1976 H H Isothemal titration calorimetry: 10-fold lower affinity (Parthier et al., 2007) GIP(17-42) B P Ha Pancreas membranes: IC50 0.5 µM B R Pan.perfusion: 32% insulin response (5 ng/ml) (Maletti et al., 1986) US US R (Tseng et al., 1996) 
